Text Search: Search by:

Refine your search with filters

Year:

All

Congress Abstracts

Tools & Skills

Publications

Congress Presentations

Videos & Podcasts

Quicksearch

P464: Assessing medication adherence in patients with inflammatory bowel disease: what do we choose, self-adherence scales or pharmacy rates?ECCO '16 Amsterdam

Year: 2016

Authors:

M. L. De Castro*¹, L. Sanromán¹, A. Martín², N. Martínez², M. Figueira¹, V. Hernández¹, J. R. Pineda¹, J. Martínez-Cadilla¹, S. Pereira¹, V. Del Campo³, J.-I. Rodríguez-Prada¹

¹Hospital Alvaro Cunqueiro. Complexo Hospitalario Universitario de Vigo. CHUVI, Gastroenterology, Vigo, Spain, ²Hospital Alvaro Cunqueiro. Complexo Hospitalario Universitario de Vigo. CHUVI, Hospital Pharmacy, Vigo, Spain, ³Hospital Alvaro Cunqueiro. Complexo Hospitalario Universitario de Vigo. CHUVI, Epidemiology, Vigo, Spain

P465: Indication-specific feasibility assessment of a placebo-controlled randomised mesalazine withdrawal study for paediatric patients with ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

N. Croft¹, W. Faubion², D. Tierens³, J. Dewulf³, D. Bwirire³, D. Stefani-Hunyady⁴, F. Cataldi*⁵

¹Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Immunobiology, London, United Kingdom, ²Mayo Clinic, Department of Gastroenterology and Hepatology, Rochester, Minnesota, United States, ³Shire, Brussels, Belgium, ⁴Shire, Lexington, Massachusetts, United States, ⁵Shire, Gastroenterology, Lexington, Massachusetts, United States

P466: Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumour necrosis factor alpha therapy: a prospective single-centre open-label studyECCO '16 Amsterdam

Year: 2016

Authors:

T. Hlavaty*, A. Krajcovicova, J. Letkovsky, I. Sturdik, T. Koller, J. Toth, M. Huorka

Comenius University, Faculty of Medicine and University Hospital Bratislava, Fifth Department of Internal Medicine, Bratislava, Slovakia

P467: The validation of the Crohn’s and Ulcerative Colitis Questionnaire–12 Plus (CUCQ-12 plus): a short quality-of-life measure for inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

S. Shwana*¹, L. Alrubaiy¹, H. Hutchings², J. Williams², A. Protheroe³, K. Mortier⁴

¹Prince Charles Hospital, Gastroenterology, Merthyr Tydfil, United Kingdom, ²College of Medicine, Swansea University, Swansea, United Kingdom, ³Royal College of Physicians,, London, United Kingdom, ⁴Royal College of Physicians, London, United Arab Emirates

P468: Long-term efficacy and safety of thiopurine in biologic-naïve Japanese patients with ulcerative colitis: a multicentre retrospective studyECCO '16 Amsterdam

Year: 2016

Authors:

T. Takagi*¹, M. Matsuura², S. Yamada², S. Bamba³, Y. Hotta¹, K. Uchiyama¹, Y. Naito¹, H. Nakase², A. Andoh³, T. Kawamura⁴, S. Katsushima⁵, T. Kusaka⁶, H. Obata⁷, T. Kogawa⁸

¹Kyoto Prefectural University of Medicine, Molecular Gastroenterology and Hepatology, Kyoto, Japan, ²Kyoto University Hospital, Department of Gastroenterology and Hepatology, Kyoto, Japan, ³Shiga University of Medical Science, Department of Medicine, Otsu, Japan, ⁴Kyoto Second Red Cross Hospital, Kyoto, Japan, ⁵National Hospital Organisation Kyoto Medical Centre, Kyoto, Japan, ⁶Kyoto Katsura Hospital, Kyoto, Japan, ⁷Obata Medical Clinic, Kyoto, Japan, ⁸Kogawa Internal Medicine Clinic, Internal Medicine Clinic, Kyoto, Japan

P469: Changes in peripheral blood lymphocyte subsets induced by azathioprine in Crohn’s disease patientsECCO '16 Amsterdam

Year: 2016

Authors:

A. Labidi*, M. Fekih, N. Ben Mustapha, S. Ben Amor, M. Serghini, L. Kallel, J. Boubaker, A. Filali

La Rabta University Hospital, Gastroenterology, Tunis, Tunisia

P470: Early change in faecal calprotectin during anti-TNFα initiation is strongly predictive of outcome in Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

P. Pavlidis*, G. Chung- Faye, P. Dubois, I. Bjarnason, B. H. Hayee

King’s College Hospital, Department of Gastroenterology, London, United Kingdom

P471: Safety analysis of multimatrix mesalazine amongst patients with ulcerative colitis or recurrent diverticulitis ≥ 55 years of ageECCO '16 Amsterdam

Year: 2016

Authors:

G. Lichtenstein¹, K. Barrett², D. Stefani-Hunyady³, F. Cataldi*⁴, J. Raskin⁵

¹University of Pennsylvania Healthy System, Inflammatory Bowel Disease Centre, Philadelphia, Pennsylvania, United States, ²Shire, Basingstoke, United Kingdom, ³Shire, Lexington, Massachusetts, United States, ⁴Shire, Gastroenterology, Lexington, Massachusetts, United States, ⁵University of Miami Health System, Gastroenterology and Internal Medicine, Miami, Florida, United States

P472: Faecal calprotectin as a biomarker of early mucosal healing in patients with ulcerative colitis naïve to adalimumab treatmentECCO '16 Amsterdam

Year: 2016

Authors:

C. Muñoz Villafranca*¹, A. Perez de Arenaza², L. Gómez³, R. Higuera⁴, A. Munagorri⁵, M. A. Ogueta⁶, S. Ibañez⁷, J. Ortiz de Zárate⁸, O. Merino³, C. Rodriguez⁹, O. Nante⁹, P. Arreba¹⁰, P. Ramirez de la Piscina¹¹, I. Rodríguez¹², A. Bernal¹³, J. A. Arévalo¹³, J. L. Cabriada¹³

¹Hospital Universitario de Basurto, Aparato Digestivo, Bilbao, Spain, ²Hospital Universitario de Basurto, Bilbao, Spain, ³Hospital Universitario de Cruces, Gastroenterology, Baracaldo, Spain, ⁴Hospital San Eloy, Gastroenterology, Baracaldo, Spain, ⁵Hospital Donostia, Gastroenterology, Donosti, Spain, ⁶Hospital de Santiago, Gastroenterology, Vitoria, Spain, ⁷Hospital Universitario de Cruces, Gastroenterology, Baracaldo, Spain, ⁸Hospital Universitario de Basurto, Gastroenterology, Bilbao, Spain, ⁹Hospital de Navarra, Gastroenterology, Pamplona, Spain, ¹⁰Hospital Universitario de Basurto, Gastroenterology, Bilbao, Spain, ¹¹Hospital de Txagorritxu, Gastroenterology, Vitoria, Spain, ¹²Hospital de Galdakao, Galdakao, Spain, ¹³Hospital de Galdácano, Gastroenterology, Galdácano, Spain

P473: Clinical and biochemical factors that influence response in inflammatory disease patients receiving tacrolimusECCO '16 Amsterdam

Year: 2016

Authors:

I. Rodríguez - Lago*^{1, 2}, O. Merino^{2, 3}, O. Nantes^{2, 4}, C. Muñoz^{2, 5}, U. Aguirre⁶, J. L. Cabriada^{1, 2}

¹Galdakao Hospital, Gastroenterology, Galdakao, Spain, ²IBD Study Group of the Basque – Navarre Society of Gastrointestinal Diseases, Pais Vasco - Navarra, Spain, ³Cruces University Hospital, Gastroenterology, Bilbao, Spain, ⁴Complejo Hospitalario de Navarra, Gastroenterology Department, Pamplona, Spain, ⁵Basurto University Hospital, Gastroenterology, Bilbao, Spain, ⁶Galdakao Hospital, Research Unit, Galdakao, Spain

P474: Assessing the position of systemic tacrolimus in the treatment of inflammatory bowel disease: systematic review and meta-analysisECCO '16 Amsterdam

Year: 2016

Authors:

M. Lie*, J. Kreijne, B. Hansen, J. van der Woude

Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands

P475: Gastroenterological and reumatological chronic patients: are there differences in individual welfare and quality of life?—a cross-observational studyECCO '16 Amsterdam

Year: 2016

Authors:

A. Stefani, M. G. Vettorato*, G. Lorenzon, T. Marcon, F. Simonetti, A. Rigo, E. V. Savarino, E. De Marchi, R. D’Incà, G. C. Sturniolo

University of Padua, Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy, Padua, Italy

P476: Fermentable carbohydrates (FODMAPs) as triggers of functional gastrointestinal symptoms in patients with quiescent inflammatory bowel disease: a double-blind, placebo-controlled, randomised, cross-over re-challenge trialECCO '16 Amsterdam

Year: 2016

Authors:

S. Cox*¹, A. Prince^{1, 2}, C. Myers^{1, 3}, P. M. Irving^{1, 4}, J. O. Lindsay⁵, M. C. Lomer^{1, 4}, K. Whelan¹

¹King’s College London, School of Medicine, Diabetes and Nutritional Sciences Division, London, United Kingdom, ²King’s College Hospital NHS Foundation Trust, Nutrition and Dietetics, London, United Kingdom, ³The Royal Surrey County Hospital NHS Trust, Nutrition and Dietetics, Guildford, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, United Kingdom, ⁵Barts Health NHS Trust, Gastroenterology, London, United Kingdom

P477: Effect of tumour necrosis factor antagonists on avoiding surgery in stricturing Crohn’s disease: a tertiary centre real-life experienceECCO '16 Amsterdam

Year: 2016

Authors:

M. Allocca*¹, G. Fiorino¹, C. Bonifacio², A. Spinelli³, A. Repici⁴, A. Malesci^{5, 6}, L. Balzarini², S. Danese^{1, 7}

¹Humanitas Research Hospital, IBD Centre, Gastroenterology, Rozzano, Milan, Italy, ²Humanitas Research Hospital, Radiology, Rozzano, Milan, Italy, ³Humanitas Research Hospital, IBD Surgery, Colo-rectal Surgery, Rozzano, Milan, Italy, ⁴Humanitas Research Hospital, Endoscopy Unit, Gastroenterology, Rozzano, Milan, Italy, ⁵Humanitas Research Hospital, Gastroenterology, Rozzano, Milan, Italy, ⁶University of Milan, Translational Medicine, Milan, Italy, ⁷Humanitas University, Biomedical Sciences, Rozzano, Milan, Italy

P478: How often high-dose budesonide is necessary for maintenance treatment of collagenous colitis? Efficacy of azathioprine to maintain budesonide-free clinical remissionECCO '16 Amsterdam

Year: 2016

Authors:

F. Fernández-Bañares*¹, M. Piqueras², D. Guagnozzi³, V. Robles⁴, A. Ruiz-Cerulla⁵, M. J. Casanova⁶, J. P. Gisbert⁶, D. Busquets⁷, A. Lucendo⁸, Y. Arguedas⁹, L. Fernández¹⁰

¹Hospital Universitari Mutua Terrassa, Gastroenterology, CIBERehd, Terrassa, Spain, ²Consorci Sanitari Terrassa, Gastroenterology, Terrassa, Spain, ³Hospital Vall d’Hebron, Gastroenterology, Barcelona, Spain, ⁴Hospital Vall d’Hebron, Department of Gastroenterology, Barcelona, Spain, ⁵Hospital de Bellvitge, Gastroenterology, L’Hospitalet de Llobregat, Spain, ⁶Hospital Universitario de La Princesa, Gastroenterology, CIBERehd, Madrid, Spain, ⁷Hospital Universitari Dr Josep Trueta, Department of Gastroenterology, Girona, Spain, ⁸Hospital General De Tomelloso, Department of Gastroenterology, Tomelloso, Spain, ⁹Hospital San Jorge, Gastroenterology, Huesca, Spain, ¹⁰Hospital University Clinic Valladolid, Department of Gastroenterology, Valladolid, Spain

P479: Hepcidin and the risk of malnutrition in inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

R. Dudkowiak*, K. Neubauer, E. Poniewierka

Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland

P480: Goals of treatment: preferences of inflammatory bowel disease patientsECCO '16 Amsterdam

Year: 2016

Authors:

F. Casellas*^{1, 2}, C. Herrera de Guise¹, V. Robles¹, E. Navarro¹, N. Borruel¹

¹Hospital Universitari Vall d’Hebron, Unitat Atenció Crohn-Colitis, Barcelona, Spain, ²Hospital Universitari Vall d’Hebron, Barcelona, Spain

P481: Effect of anti-TNFα therapy with daily physical activity in patients with Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

F. A. Lucca, C. Malaguti, A. L. Cabalzar, L. A. Chebli, T. C. R. Ribeiro*, P. D. Gaburri, J. M. F. Chebli

Universidade Federal de Juiz de Fora, Gastroenterology, Juiz de Fora, Brazil

P482: Different characteristics of inflammatory bowel disease patients between tertiary referral centres and secondary hospitalsECCO '16 Amsterdam

Year: 2016

Authors:

K. H. Song*¹, Y. J. Lee², K. O. Kim³, H. S. Lee⁴, E. S. Kim², J. I. Koo¹, J. S. Jeong¹, W. S. Seo¹

¹Goo Hospital, General Surgery, Daegu, South Korea, ²Keimyung University School of Medicine, Internal Medicine, Daegu, South Korea, ³Yeungnam University College of Medicine, Internal Medicine, Daegu, South Korea, ⁴Kyungpook National University School of Medicine, Department of Internal Medicine, Daegu, South Korea

P483: Differences in biologic therapy utilisation amongst early and late-onset inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

S. Raimundo Fernandes*, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, L. Correia, J. Velosa

Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal